Selpercatinib

Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection"). Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing